Form 4: Palatin Director Alan Dunton Boosts Equity Holdings

Palatin Technologies Director Alan W. Dunton acquired 2,000 restricted stock units and 2,400 stock options under the company's 2011 Stock Incentive Plan.

Summary

• Director Alan W. Dunton acquired 2,000 shares of Common Stock in the form of Restricted Share Units (RSUs) on December 9, 2025, with a transaction price of $0 per unit.
• The first grant of 1,000 RSUs vests on December 9, 2026.
• The second grant of 1,000 RSUs vests 50% on December 9, 2026, and the remaining 50% on December 9, 2027.
• Dunton also acquired 2,400 Stock Options (right to buy) with an exercise price of $21.38 per share on December 9, 2025, with a transaction price of $0.
• The first grant of 1,200 Stock Options vests on December 9, 2026, and expires on December 9, 2035. It is prorated if the director's service ends before December 31, 2026.
• The second grant of 1,200 Stock Options vests 50% on December 9, 2026, and the remaining 50% on December 9, 2027, and expires on December 9, 2026.
• All grants were made by the Compensation Committee under the 2011 Stock Incentive Plan and were pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Dunton beneficially owns 14,081 shares of Common Stock and 25,999 derivative securities (Stock Options).

Sentiment

Score: 6

Explanation: The filing reports routine equity grants to a director, which is generally viewed as a positive for aligning management interests with shareholders. It does not contain any negative financial or operational news.

Positives

• The acquisition of additional equity by a director aligns their interests with those of shareholders, potentially motivating long-term value creation.
• The grants were made under an established 2011 Stock Incentive Plan, indicating a structured approach to executive and director compensation.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transactions.

Industry Context

The granting of restricted stock units and stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of long-term incentive compensation to align leadership interests with shareholder value creation.

Comparison to Industry Standards

• Equity compensation for directors, including RSUs and stock options, is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The use of a 2011 Stock Incentive Plan indicates a mature and established compensation framework, comparable to those seen in many peer companies.
• The vesting schedules, typically over several years, are consistent with industry norms designed to promote long-term retention and performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with long-term shareholder value, potentially fostering more strategic decision-making.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The restricted share units and stock options will vest according to their specified schedules on December 9, 2026, and December 9, 2027.

Key Dates

Keywords

Palatin Technologies, PTN, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, 10b5-1 Plan